483
AstraZeneca Nijmegen B.V.FDA 483 - AstraZeneca Nijmegen B.V. - September 19, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of MedImmune Pharma BV in Nijmegen, The Netherlands, revealed two significant observations related to drug product manufacturing. The firm was cited for inadequate deviation investigations, specifically regarding failed HEPA filters without a proper product impact assessment. Additionally, operators failed to follow procedures designed to prevent microbiological contamination of sterile drug products, exhibiting poor aseptic technique.
Open in Dashboard
ID · cfae0374-c679-4edd-9838-4f8b3339c100